StockNews.com initiated coverage on shares of IRIDEX (NASDAQ:IRIX – Get Free Report) in a research report issued on Wednesday. The brokerage set a “hold” rating on the medical equipment provider’s stock.
IRIDEX Price Performance
Shares of IRIX stock opened at $1.64 on Wednesday. The stock’s fifty day simple moving average is $1.70 and its 200 day simple moving average is $1.76. IRIDEX has a one year low of $1.27 and a one year high of $3.65. The firm has a market cap of $27.28 million, a price-to-earnings ratio of -2.45 and a beta of 0.84. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.54 and a quick ratio of 0.85.
IRIDEX (NASDAQ:IRIX – Get Free Report) last issued its earnings results on Tuesday, November 12th. The medical equipment provider reported ($0.12) EPS for the quarter. The firm had revenue of $11.58 million during the quarter. IRIDEX had a negative net margin of 22.79% and a negative return on equity of 192.95%. During the same quarter in the previous year, the company earned ($0.11) EPS.
About IRIDEX
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.
See Also
- Five stocks we like better than IRIDEX
- Why is the Ex-Dividend Date Significant to Investors?
- Price Plunge in Roblox Presents Opportunity for Robust Gains
- How to Capture the Benefits of Dividend Increases
- Billions in Buybacks: 4 Stocks Rewarding Shareholders Now
- Low PE Growth Stocks: Unlocking Investment Opportunities
- 3 Steel Stocks to Gain Strength as Tariffs Reshape the Market
Receive News & Ratings for IRIDEX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IRIDEX and related companies with MarketBeat.com's FREE daily email newsletter.